Heme Malignancy
Seraseq Myeloid ctDNA Mix AF1%
Material Number
0710-2649
Size
1 x 25 µL
Inventory Status
In Stock
Unit
EA
Details
Resources
Specifications
Frequently Asked Questions
To help clinical labs performing NGS-based myeloid testing characterize the limit of detection (LOD) of their liquid biopsy assays and validate robust sensitivity, SeraCare has developed myeloid cancer NGS reference material in ctDNA format to ensure compatibility with existing and emerging myeloid assays.
- Single sample with 25 clinically relevant DNA variants across 17 genes
- Expert-designed to ensure coverage across important variants (mix of SNVs, INDELs, and ITD) at relevant allele frequencies (1%, 0.5%, 0.1%, WT)
- Built with innovative technology to produce patient-like sample performance in NGS assays
- Variants precisely quantified using highly sensitive digital PCR assays, and blended with a single well-characterized genomic background (GM24385)
- Validated by targeted NGS panels
- Manufactured in GMP-compliant, ISO 13485-certified facilities
Seraseq ctDNA Myeloid Mix AF1%, AF0.5%, AF0.1%, WT Package Insert
Doc type
Package Insert
Download
Seraseq ctDNA Myeloid Mix Non-Requirement Letter
Doc type
Safety Data Sheet (Non-Requirement Letter)
Download
Seraseq Myeloid Reference Materials: DNA, RNA Fusion, ctDNA Product Sheet
Doc type
Product Sheet
Download
Technical Spreadsheet for Seraseq Myeloid ctDNA Mixes
Doc type
Technical Spreadsheet
Download
Seraseq ctDNA Myeloid Mix AF1%, AF0.5%, AF0.1%, WT
Doc type
Safety Data Sheet (Non-Requirement Letter)
Download
Seraseq ctDNA Myeloid Mix 1%
Product Specifications | |
# of Variants | 25 |
Allele Frequency | 1% |
Concentrations | 15 ng/µL |
Amount | 375 ng (single vial) |
Buffer | 1 mM Tris, 0.1 mM EDTA, 10 mM KCl, pH 8.0 |
Somatic Cancer FAQs
Review the common questions we receive from our customers and the responses we provide.